Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $65
Structure Therapeutics Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR) and AbSci (ABSI)
Buy Rating Affirmed for Structure Therapeutics on Strong Pipeline and Undervalued Patent Portfolio
Don't Forget This Startup's Weight-Loss Pill, Analyst Says -- Barrons.com
Structure Therapeutics Analyst Ratings
Leerink Partners Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $136
Buy Rating Affirmed: Undervalued Structure Therapeutics Poised for Growth With Strong R&D Pipeline and Strategic Partnerships
Leerink Partners Maintains Structure Therapeutics(GPCR.US) With Buy Rating
Buy Rating Backed by Strategic Partnership Opportunities and Strong Patent Portfolio for Structure Therapeutics
Analysts' Top Healthcare Picks: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Armata Pharmaceuticals (ARMP)
Structure Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and UnitedHealth (UNH)
Structure Therapeutics Analyst Ratings
Structure Therapeutics Analyst Ratings
Structure Therapeutics (NASDAQ:GPCR): Analysts Say This GLP-1 Stock Can Rise 130%
Buy Rating on Structure Therapeutics' GSBR-1290 for Non-T2D Obesity Potential
Structure Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), 4D Molecular Therapeutics (FDMT) and Sanofi (OtherSNYNF)